• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Veru Inc. (Amendment)

    2/6/24 4:27:50 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VERU alert in real time by email
    SC 13G/A 1 tm245362d2_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G/A

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 2)

     

    Veru Inc.

    (Name of Issuer)

     

    Common stock, par value $0.01 per share (“Common Stock”)

    (Title of Class of Securities)

     

    92536C103

    (CUSIP Number)

     

    January 16, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨  Rule 13d-1(b)

     

    x  Rule 13d-1(c)

     

    ¨  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    1.

    Names of Reporting Persons

     

    Phillip Frost, M.D.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨ (b) x

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States

     

    Number of
    Shares
    Beneficially
    Owned By
    Each
    Reporting
    Person
    With:
    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    5,100,253(1)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    5,100,253(1)

     

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,100,253 (1)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    3.5%(2)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1) Includes 5,100,253 shares of Common Stock of the Issuer held by Frost Gamma Investments Trust (“FGIT”), of which Dr. Phillip Frost is the trustee of FGIT. Frost Gamma L.P. is the sole and exclusive beneficiary of FGIT. Dr. Phillip Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc. and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Phillip Frost is also the sole shareholder of Frost-Nevada Corporation.

     

    (2) The calculation of all percentages set forth herein is based on 146,381,186 shares of Common Stock outstanding as of January 16, 2024, as reported on the Issuer’s Proxy Statement, and filed with the Securities and Exchange Commission on Schedule 14A on January 26, 2024.

     

     

     

     

    1.

    Names of Reporting Persons

     

    Frost Gamma Investments Trust

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨ (b) x

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Florida

     

    Number of
    Shares
    Beneficially
    Owned By
    Each
    Reporting
    Person
    With:
    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    5,100,253(1)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    5,100,253(1)

     

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,100,253 (1)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    3.5%

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1) Includes 5,100,253 shares of Common Stock of the Issuer held by FGIT, of which Dr. Phillip Frost is the trustee of FGIT. Frost Gamma L.P. is the sole and exclusive beneficiary of FGIT. Dr. Phillip Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc. and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Phillip Frost is also the sole shareholder of Frost-Nevada Corporation.

     

     

     

     

    Item 1(a). Name of Issuer
      Veru Inc. (the “Issuer”)

     

    Item 1(b). Address of the Issuer’s Principal Executive Offices
      2916 N. Miami Avenue, Suite 1000, Miami, Florida 33127

     

    Item 2(a). Names of Persons Filing
      Phillip Frost, M.D.
      Frost Gamma Investments Trust

     

    Item 2(b). Address of the Principal Business Office, or if none, Residence:
      Dr. Phillip Frost - 4400 Biscayne Blvd. Miami, FL 33137
      Frost Gamma Investments Trust - 4400 Biscayne Blvd. Miami, FL 33137

     

    Item 2(c). Citizenship
      Phillip Frost, M.D. - United States
      Frost Gamma Investments Trust is organized under the laws of State of Florida

     

    Item 2(d). Title of Class of Securities
      Common stock, par value $0.01 per share

     

    Item 2(e). CUSIP Number
      92536C103

     

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

    ¨  (a) Broker or Dealer registered under Section 15 of the Exchange Act.
       
    ¨ (b) Bank as defined in Section 3(a)(b) or the Exchange Act.
       
    ¨ (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act.
       
    ¨ (d) Investment company registered under Section 8 of the Investment Company Act.
       
    ¨ (e) An Investment adviser in accordance with Rule 13d-1 (b)(1)(ii)(e).
       
    ¨ (f) An employee benefit plan or endowment fund in accordance with Rule 13d 1(b)(1)(ii)(f).
       
    ¨ (g) A Parent Holding Company or control person in accordance with Rule 13d 1(b)(1)(ii)(g).
       
    ¨ (h) A Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act.
       
    ¨ (i) A Church Plan that is excluded from the definition of an investment company under Section 3 (c)(14) of the Investment Company Act.
       
    ¨ (j) Group, in accordance with Rule 13d-1 (b)(1)(ii)(j).
       
    x  Not applicable

     

     

     

     

    Item 4. Ownership

     

    The responses to Items 5-11 of the cover pages of this Schedule 13G are incorporated herein by reference.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a) Amount Beneficially Owned:

    Phillip Frost, M.D. – 5,100,253

    Frost Gamma Investments Trust – 5,100,253

     

    (b) Percent of Class:

    Phillip Frost, M.D. – 3.5%

    Frost Gamma Investments Trust – 3.5%

     

    The calculation of all percentages set forth herein is based on 146,381,186 shares of Common Stock outstanding as of January 16, 2024, as reported on the Issuer’s Proxy Statement, filed with the Securities and Exchange Commission on Schedule 14A on January 26, 2024.

     

    (c) Number of shares as to which such person has:

     

    (i) sole power to vote or to direct the vote:
      Phillip Frost, M.D. – 0
      Frost Gamma Investments Trust - 0

     

    (ii) shared power to vote or to direct the vote:
      Phillip Frost, M.D. – 5,100,253(1)
      Frost Gamma Investments Trust – 5,100,253

     

    (iii) sole power to dispose or to direct the disposition of:
      Phillip Frost, M.D. – 0
      Frost Gamma Investments Trust - 0

     

    (iv) shared power to dispose or to direct the disposition of:
      Phillip Frost, M.D. – 5,100,253(1)
      Frost Gamma Investments Trust – 5,100,253

     

    (1) Includes 5,100,253 shares of Common Stock held as of the date hereof by Frost Gamma Investments Trust (“FGIT”), of which Dr. Phillip Frost is the trustee of FGIT. Frost Gamma L.P. is the sole and exclusive beneficiary of FGIT. Dr. Phillip Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc. and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Phillip Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not Applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

     

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable

     

     

     

     

    Item 9. Notice of Dissolution of Group

     

    Not Applicable

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 6, 2024 By: /s/ Phillip Frost, M.D.
      Name: Phillip Frost, M.D.
      Title: Phillip Frost, M.D., Individually
       
      FROST GAMMA INVESTMENTS TRUST
         
    Dated: February 6, 2024 By: /s/ Phillip Frost, M.D.
      Name: Phillip Frost, M.D.
      Title: Trustee

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations

    (See 18 U.S.C. 1001)

     

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit 1 Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

     

     

    Get the next $VERU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VERU

    DatePrice TargetRatingAnalyst
    5/14/2024$5.00Buy
    B. Riley Securities
    3/28/2024$3.00Outperform
    Raymond James
    6/7/2023$1.00Underperform → Hold
    Jefferies
    More analyst ratings

    $VERU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Veru Participates in a Virtual Investor KOL Connect Segment

      -- Moderated discussion with preeminent obesity expert, Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder, of Veru -- MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the release of a Virtual Investor KOL segment featuring Louis J. Aronne, MD, FACP. As part of the segment, Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder, of Veru and Dr. Aronne discussed obesity and GLP-1s, the current treatment landscape and areas of unmet need, highlighting Veru'

      5/8/25 9:25:00 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

      --Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of calendar 2025 -- --With positive Phase 2b QUALITY study, Veru plans for end of Phase 2 meeting with FDA to discuss Phase 3 clinical program -- --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for

      5/8/25 6:30:00 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8

      MIAMI, May 01, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Thursday, May 8, 2025, at 8:00 a.m. ET to discuss its fiscal 2025 second quarter financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page of the Company's website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call. A

      5/1/25 8:30:00 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Hyun Grace

      4 - VERU INC. (0000863894) (Issuer)

      5/8/25 3:57:21 PM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Katzovitz Loren Mark

      4 - VERU INC. (0000863894) (Issuer)

      5/8/25 3:49:39 PM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Admin Officer and CFO Greco Michele

      4 - VERU INC. (0000863894) (Issuer)

      5/8/25 3:39:39 PM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERU
    Financials

    Live finance-specific insights

    See more
    • Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

      --Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of calendar 2025 -- --With positive Phase 2b QUALITY study, Veru plans for end of Phase 2 meeting with FDA to discuss Phase 3 clinical program -- --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for

      5/8/25 6:30:00 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8

      MIAMI, May 01, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Thursday, May 8, 2025, at 8:00 a.m. ET to discuss its fiscal 2025 second quarter financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page of the Company's website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call. A

      5/1/25 8:30:00 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

      --Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater fat loss and improvement of physical function-- -- The Independent Data Monitoring Committee met this week on February 10, 2025 to evaluate the unblinded safety Phase 2b QUALITY data and recommended to continue the QUALITY extension study as designed-- --Topline results of the Phase 2b extension maintenance study to reduce fat regain following discontinuation of GLP-1 RA are expected in the second quarter of calendar 2025-- --Company announces new cardiometabolic indication for sabiza

      2/13/25 6:30:00 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERU
    SEC Filings

    See more
    • SEC Form PRE 14A filed by Veru Inc.

      PRE 14A - VERU INC. (0000863894) (Filer)

      5/9/25 4:15:24 PM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Veru Inc.

      10-Q - VERU INC. (0000863894) (Filer)

      5/8/25 11:51:12 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Veru Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - VERU INC. (0000863894) (Filer)

      5/8/25 7:01:00 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on Veru with a new price target

      B. Riley Securities initiated coverage of Veru with a rating of Buy and set a new price target of $5.00

      5/14/24 8:03:44 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James initiated coverage on Veru with a new price target

      Raymond James initiated coverage of Veru with a rating of Outperform and set a new price target of $3.00

      3/28/24 7:50:24 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Veru upgraded by Jefferies with a new price target

      Jefferies upgraded Veru from Underperform to Hold and set a new price target of $1.00

      6/7/23 7:41:34 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERU
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for ENTADFI issued to VERU INC

      Submission status for VERU INC's drug ENTADFI (ORIG-1) with active ingredient FINASTERIDE;TADALAFIL has changed to 'Approval' on 12/09/2021. Application Category: NDA, Application Number: 215423, Application Classification: Type 4 - New Combination

      12/13/21 8:12:46 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rankowitz Michael L bought $84,351 worth of shares (150,000 units at $0.56), increasing direct ownership by 150% to 250,000 units (SEC Form 4)

      4 - VERU INC. (0000863894) (Issuer)

      2/20/25 10:00:11 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fisch Harry bought $5,000 worth of shares (4,000 units at $1.25), increasing direct ownership by 0.52% to 774,736 units (SEC Form 4)

      4 - VERU INC. (0000863894) (Issuer)

      5/28/24 5:04:02 PM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barnette K Gary bought $6,696 worth of shares (5,000 units at $1.34) (SEC Form 4)

      4 - VERU INC. (0000863894) (Issuer)

      5/24/24 6:57:00 PM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Veru Inc.

      SC 13G/A - VERU INC. (0000863894) (Subject)

      11/12/24 9:34:37 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Veru Inc.

      SC 13G/A - VERU INC. (0000863894) (Subject)

      11/4/24 4:19:00 PM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Veru Inc.

      SC 13G - VERU INC. (0000863894) (Subject)

      4/24/24 4:16:01 PM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERU
    Leadership Updates

    Live Leadership Updates

    See more
    • Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board

      MIAMI, FL, June 01, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, today announced the appointment of Erik Swenson, M.D., a world-renowned pulmonologist specializing in critical care, and Robert Schooley, M.D., an accomplished infectious disease physician and researcher, to its Infectious Disease Scientific Advisory Board (SAB) to join David D. Ho, M.D., a trailblazer of infectious disease viral research and therapeutic development, who is Chairman of the SAB. "We are pleased to share that Dr. Erik Swenson and

      6/1/23 8:30:00 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board

      MIAMI. FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced the appointment of David D. Ho, M.D., a trailblazer of infectious disease viral research and therapeutic development, as Chairman of its Scientific Advisory Board (SAB). "Today's appointment of Dr. Ho as Chairman of Veru's SAB illustrates our commitment to building a team of scientific experts to support our goal of developing and delivering life-saving therapies to patients with COVID-19 and other viral ARDS-related diseases," said Mitchell Steiner, M.D., Chairman, Presi

      1/10/23 8:30:00 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Veru Announces Appointment of Jason Davies to Lead EMEA, LATAM and APAC Infectious Disease Franchise for Veru International Focused on Hospitalized COVID-19 Patients

      MIAMI, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the appointment of Jason Davies as Executive Vice President – General Manager of Europe, the Middle East and Africa (EMEA), Latin America (LATAM), and Asia Pacific (APAC) for Veru's Infectious Disease Franchise for Veru International. Most recently Mr. Davies had been the EMEA Head of Launch Excellence – Pharmaceutical Portfolio at Janssen (Johnson & Johnson) where he was responsible for creating and leading a new organization to enhan

      8/19/22 8:30:00 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care